It must be considered noteworthy the significant ICI-based regimens’ antitumor activity in RCC with sarcomatoid and rhabdoid features (S/R RCC), whose response to classic RCC treatments (including anti-angiogenic agents as well as mTOR inhibitors) is poor [117]. Here, MTOR is linked to renal cell carcinoma.